126 related articles for article (PubMed ID: 38530204)
1. Dual and triple modulator therapy for chronic rhinosinusitis in cystic fibrosis patients.
Uyttebroek S; Claeyssens C; Jorissen M; Dupont L; Van Gerven L
Rhinology; 2024 Mar; ():. PubMed ID: 38530204
[TBL] [Abstract][Full Text] [Related]
2. Impact of elexacaftor/tezacaftor/ivacaftor on bacterial cultures from people with cystic fibrosis.
Beck MR; Hornick DB; Pena TA; Singh SB; Wright BA
Pediatr Pulmonol; 2023 May; 58(5):1569-1573. PubMed ID: 36807558
[TBL] [Abstract][Full Text] [Related]
3. Longitudinal profiling of the intestinal microbiome in children with cystic fibrosis treated with elexacaftor-tezacaftor-ivacaftor.
Reasoner SA; Bernard R; Waalkes A; Penewit K; Lewis J; Sokolow AG; Brown RF; Edwards KM; Salipante SJ; Hadjifrangiskou M; Nicholson MR
mBio; 2024 Feb; 15(2):e0193523. PubMed ID: 38275294
[TBL] [Abstract][Full Text] [Related]
4. Effects of Elexacaftor/Tezacaftor/Ivacaftor Therapy on CFTR Function in Patients with Cystic Fibrosis and One or Two
Graeber SY; Vitzthum C; Pallenberg ST; Naehrlich L; Stahl M; Rohrbach A; Drescher M; Minso R; Ringshausen FC; Rueckes-Nilges C; Klajda J; Berges J; Yu Y; Scheuermann H; Hirtz S; Sommerburg O; Dittrich AM; Tümmler B; Mall MA
Am J Respir Crit Care Med; 2022 Mar; 205(5):540-549. PubMed ID: 34936849
[No Abstract] [Full Text] [Related]
5. Real-world outcomes and direct care cost before and after elexacaftor/tezacaftor/ivacaftor initiation in commercially insured members with cystic fibrosis.
Marshall LZ; Espinosa R; Starner CI; Gleason PP
J Manag Care Spec Pharm; 2023 Jun; 29(6):599-606. PubMed ID: 37276039
[No Abstract] [Full Text] [Related]
6. Impact of Elexacaftor/Tezacaftor/Ivacaftor on Healthcare Resource Utilization and Associated Costs Among People With Cystic Fibrosis in the US: A Retrospective Claims Analysis.
Schechter MS; Sabater-Anaya N; Oster G; Weycker D; Wu H; Arteaga-Solis E; Bagal S; McGarry LJ; Van Brunt K; Geiger JM
Pulm Ther; 2023 Dec; 9(4):479-498. PubMed ID: 37874528
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 Through 11 Years of Age with Cystic Fibrosis Heterozygous for
Mall MA; Brugha R; Gartner S; Legg J; Moeller A; Mondejar-Lopez P; Prais D; Pressler T; Ratjen F; Reix P; Robinson PD; Selvadurai H; Stehling F; Ahluwalia N; Arteaga-Solis E; Bruinsma BG; Jennings M; Moskowitz SM; Noel S; Tian S; Weinstock TG; Wu P; Wainwright CE; Davies JC
Am J Respir Crit Care Med; 2022 Dec; 206(11):1361-1369. PubMed ID: 35816621
[No Abstract] [Full Text] [Related]
8. The use of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis postliver transplant: A case series.
Ragan H; Autry E; Bomersback T; Hewlett J; Kormelink L; Safirstein J; Shanley L; Lubsch L
Pediatr Pulmonol; 2022 Feb; 57(2):411-417. PubMed ID: 34850610
[TBL] [Abstract][Full Text] [Related]
9. Real-world safety and effectiveness of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis: Interim results of a long-term registry-based study.
Bower JK; Volkova N; Ahluwalia N; Sahota G; Xuan F; Chin A; Weinstock TG; Ostrenga J; Elbert A
J Cyst Fibros; 2023 Jul; 22(4):730-737. PubMed ID: 36963986
[TBL] [Abstract][Full Text] [Related]
10. Elexacaftor/Tezacaftor/Ivacaftor Treatment and Depression-related Events.
Ramsey B; Correll CU; DeMaso DR; McKone E; Tullis E; Taylor-Cousar JL; Chu C; Volkova N; Ahluwalia N; Waltz D; Tian S; Mall MA
Am J Respir Crit Care Med; 2024 Feb; 209(3):299-306. PubMed ID: 37890129
[No Abstract] [Full Text] [Related]
11. Effects of Elexacaftor/Tezacaftor/Ivacaftor Therapy on Lung Clearance Index and Magnetic Resonance Imaging in Patients with Cystic Fibrosis and One or Two
Graeber SY; Renz DM; Stahl M; Pallenberg ST; Sommerburg O; Naehrlich L; Berges J; Dohna M; Ringshausen FC; Doellinger F; Vitzthum C; Röhmel J; Allomba C; Hämmerling S; Barth S; Rückes-Nilges C; Wielpütz MO; Hansen G; Vogel-Claussen J; Tümmler B; Mall MA; Dittrich AM
Am J Respir Crit Care Med; 2022 Aug; 206(3):311-320. PubMed ID: 35536314
[No Abstract] [Full Text] [Related]
12. Post-approval studies with the CFTR modulators Elexacaftor-Tezacaftor-Ivacaftor.
Tümmler B
Front Pharmacol; 2023; 14():1158207. PubMed ID: 37025483
[TBL] [Abstract][Full Text] [Related]
13. Clinical efficacy of elexacaftor-tezacaftor-ivacaftor in an adolescent with homozygous G85E cystic fibrosis.
Stekolchik E; Saul D; Chidekel A
Respir Med Case Rep; 2022; 40():101775. PubMed ID: 36411821
[TBL] [Abstract][Full Text] [Related]
14. Elexacaftor/tezacaftor/ivacaftor projected survival and long-term health outcomes in people with cystic fibrosis homozygous for F508del.
Lopez A; Daly C; Vega-Hernandez G; MacGregor G; Rubin JL
J Cyst Fibros; 2023 Jul; 22(4):607-614. PubMed ID: 36849331
[TBL] [Abstract][Full Text] [Related]
15. Longitudinal Profiling of the Intestinal Microbiome in Children with Cystic Fibrosis Treated with Elexacaftor-Tezacaftor-Ivacaftor.
Reasoner SA; Bernard R; Waalkes A; Penewit K; Lewis J; Sokolow AG; Brown RF; Edwards KM; Salipante SJ; Hadjifrangiskou M; Nicholson MR
medRxiv; 2023 Nov; ():. PubMed ID: 37645804
[TBL] [Abstract][Full Text] [Related]
16. Cystic fibrosis: desensitization in delayed hypersensitivity reactions to elexacaftor/tezacaftor/ivacaftor.
Gómez-Ganda L; Galván-Blasco P; Fernández-Polo A; Cardona V; García-Palop B; Parramón-Teixidó CJ; Polverino E; Álvarez-Fernández A
Front Pharmacol; 2024; 15():1392986. PubMed ID: 38933680
[No Abstract] [Full Text] [Related]
17. Poor tolerability of cystic fibrosis transmembrane conductance regulator modulator therapy in lung transplant recipients.
Doligalski CT; McKinzie CJ; Yang A; Lobo LJ; Coakley R
Pharmacotherapy; 2022 Jul; 42(7):580-584. PubMed ID: 35689451
[TBL] [Abstract][Full Text] [Related]
18. Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with Phe508del mutation: Evidence from randomized controlled trials.
He R; Lin F; Deng Z; Yu B
SAGE Open Med; 2024; 12():20503121231225874. PubMed ID: 38249954
[TBL] [Abstract][Full Text] [Related]
19. Elexacaftor-Tezacaftor- Ivacaftor improves sinonasal outcomes in cystic fibrosis.
Stapleton AL; Kimple AJ; Goralski JL; Nouraie SM; Branstetter BF; Shaffer AD; Pilewski JM; Senior BA; Lee SE; Zemke AC
J Cyst Fibros; 2022 Sep; 21(5):792-799. PubMed ID: 35300931
[TBL] [Abstract][Full Text] [Related]
20. Short-Term Effects of Elexacaftor/Tezacaftor/Ivacaftor Combination on Glucose Tolerance in Young People With Cystic Fibrosis-An Observational Pilot Study.
Korten I; Kieninger E; Krueger L; Bullo M; Flück CE; Latzin P; Casaulta C; Boettcher C
Front Pediatr; 2022; 10():852551. PubMed ID: 35529332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
